These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 9074847)
41. Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single-center, randomized, double-blinded, placebo-controlled clinical trial on Mexican patients (skin type III-IV). Tirado-Sánchez A; Espíndola YS; Ponce-Olivera RM; Bonifaz A J Cosmet Dermatol; 2013 Jun; 12(2):103-7. PubMed ID: 23725303 [TBL] [Abstract][Full Text] [Related]
42. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. Tanghetti E; Dhawan S; Green L; Del Rosso J; Draelos Z; Leyden J; Shalita A; Glaser DA; Grimes P; Webster G; Barnett P; Le Gall N J Drugs Dermatol; 2010 May; 9(5):549-58. PubMed ID: 20480800 [TBL] [Abstract][Full Text] [Related]
43. [Pharma-Clinics. The drug of the month. Adapalene (Differin gel)]. Bonardeaux C; de la Brassinne M Rev Med Liege; 1998 Feb; 53(2):109-10. PubMed ID: 9564232 [TBL] [Abstract][Full Text] [Related]
44. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Dunlap FE; Mills OH; Tuley MR; Baker MD; Plott RT Br J Dermatol; 1998 Oct; 139 Suppl 52():17-22. PubMed ID: 9990416 [TBL] [Abstract][Full Text] [Related]
45. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study. Kawashima M; Harada S; Loesche C; Miyachi Y J Dermatol Sci; 2008 Mar; 49(3):241-8. PubMed ID: 18063345 [TBL] [Abstract][Full Text] [Related]
46. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. Thiboutot D; Pariser DM; Egan N; Flores J; Herndon JH; Kanof NB; Kempers SE; Maddin S; Poulin YP; Wilson DC; Hwa J; Liu Y; Graeber M; J Am Acad Dermatol; 2006 Feb; 54(2):242-50. PubMed ID: 16443054 [TBL] [Abstract][Full Text] [Related]
47. Community-based trial results of combination clindamycin 1%--benzoyl peroxide 5% topical gel plus tretinoin microsphere gel 0.04% or 0.1% or adapalene gel 0.1% in the treatment of moderate to severe acne. Kircik L Cutis; 2007 Jul; 80(1 Suppl):10-4. PubMed ID: 17824581 [TBL] [Abstract][Full Text] [Related]
49. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Langner A; Chu A; Goulden V; Ambroziak M Br J Dermatol; 2008 Jan; 158(1):122-9. PubMed ID: 18047518 [TBL] [Abstract][Full Text] [Related]
50. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Tenaud I; Khammari A; Dreno B Exp Dermatol; 2007 Jun; 16(6):500-6. PubMed ID: 17518990 [TBL] [Abstract][Full Text] [Related]
51. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066 [TBL] [Abstract][Full Text] [Related]
52. Topical retinoids in acne vulgaris: update on efficacy and safety. Thielitz A; Gollnick H Am J Clin Dermatol; 2008; 9(6):369-81. PubMed ID: 18973403 [TBL] [Abstract][Full Text] [Related]
53. Adapalene 0.1% gel has low skin irritation potential even when applied immediately after washing. Dunlap FE; Baker MD; Plott RT; Verschoore M Br J Dermatol; 1998 Oct; 139 Suppl 52():23-5. PubMed ID: 9990417 [TBL] [Abstract][Full Text] [Related]
55. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Gollnick HP; Draelos Z; Glenn MJ; Rosoph LA; Kaszuba A; Cornelison R; Gore B; Liu Y; Graeber M; Br J Dermatol; 2009 Nov; 161(5):1180-9. PubMed ID: 19466959 [TBL] [Abstract][Full Text] [Related]
56. Pharmacology and chemistry of adapalene. Shroot B; Michel S J Am Acad Dermatol; 1997 Jun; 36(6 Pt 2):S96-103. PubMed ID: 9204085 [TBL] [Abstract][Full Text] [Related]
57. Adapalene 0.1% gel has low skin-irritation potential. Verschoore M; Poncet M; Czernielewski J; Sorba V; Clucas A J Am Acad Dermatol; 1997 Jun; 36(6 Pt 2):S104-9. PubMed ID: 9204086 [TBL] [Abstract][Full Text] [Related]
58. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides. Eichenfield LF; Draelos Z; Lucky AW; Hebert AA; Sugarman J; Stein Gold L; Rudisill D; Liu H; Manna V J Drugs Dermatol; 2013 Jun; 12(6):611-8. PubMed ID: 23839175 [TBL] [Abstract][Full Text] [Related]
59. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. Pariser DM; Westmoreland P; Morris A; Gold MH; Liu Y; Graeber M J Drugs Dermatol; 2007 Sep; 6(9):899-905. PubMed ID: 17941361 [TBL] [Abstract][Full Text] [Related]
60. An update of recent clinical trials examining adapalene and acne. Wolf JE J Eur Acad Dermatol Venereol; 2001; 15 Suppl 3():23-9. PubMed ID: 11843230 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]